In a multicenter phase 2 study, the NOA-12 study prospectively investigated the question of whether a combination therapy with BIBF1120 (inhibitor of VEGFR2, FGFR and PDGFR) and re-radiation for patients with first or second glioblastoma recurrence results in a favorable signal for freedom from progression after six months. In the planned interim analysis after observation of 19 patients in the experimental arm over a period of six months, there was no positive signal for an improvement in PFS6 compared to the control arm, so that recruitment of the study was terminated prematurely.